Nanosonics Limited · ASX:NAN
Nanosonics — Wilsons HTM Life Sciences Investment Conference (October 2008)
25 slides from Nanosonics's conference presentation, Oct 16, 2008
Slide 1: Wilsons HTM Life Sciences Investment Conference – Show Me The Money
For personal use only Wilsons HTM Life Sciences Investment Conference “Show Me The Money” David Radford CEO 16th October 2008
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, fina
Slide 3: An entrepreneurial, financially strong company headquartered in Sydney, Australia
For personal use only … is an entrepreneurial, financially strong company, headquartered in Sydney, Australia
Slide 4: Key Investment Highlights
Key Investment Highlights For personal use only 9 CE Mark obtained May 08 9 EN ISO 13485:2003 quality approval 9 IP – portfolio of 10 patent families 9 Appointment of dealers on plan 9 Manufacturing on plan for Jan 09 9 Release in Australia on plan pending TGA approval 9 Strong product pipeline deve
Slide 5: Funding
Funding For personal use only • $ 12.25 million: Pre-IPO funding • $ 5 million: Australian Government R&D grants • $ 27 million: ASX Listing • $ 2 million: 3M Corporation • Fully funded commercialisation strategy
Slide 6: Business Metrics
Business Metrics For personal use only Category Date Amount Quoted shares on issue @ 15 October 08 103 million Total shares on issue @ 15 October 08 195 million* Share price @ 15 October 08 A$ 0.16 Market capitalisation @ 15 October 08 A$ 58.5 million Cash on hand @ 30 September 08 A$ 22 million Cas
Slide 7: Intellectual Property
Intellectual Property For personal use only • Nanosonics IP, including product and platform technology, is protected by multiple patents • Growing portfolio of 10 patent family applications internationally • Global protection strategy • All significant markets and manufacturing regions • Covers sign
Slide 8: Why Disinfection & Sterilisation
Why Disinfection & Sterilisation For personal use only • Infections are a worldwide and widespread problem • Australia: 150,000 healthcare associated infections and 7,000 deaths each year • US: 2 million healthcare associated infections and 100,000 deaths each year • Europe: Significant rise of MRSA
Slide 9: Setting World Class Standards
Setting World Class Standards For personal use only
Slide 10: NanoNebulant™ Technology
NanoNebulant™ Technology For personal use only
Slide 11: Competitive Advantages of NanoNebulant Technology
Competitive Advantages of NanoNebulant Technology For personal use only Po Fa Op M Sc En in to st er at co ater a la fri vir fc or m ial bl en on pa s e dl m ar f rie tib y en e nd ili ta ly ty l ly
Slide 12: Commercialisation of a Breakthrough Technology
For personal use only Commercialisation of a Breakthrough Technology
Slide 13: Ultrasound transducer as a vector for nosocomial infection
Ultrasound transducer as a vector for nosocomial infection For personal use only • Transducers used for transesophageal, transvesical, transvaginal, transrectal and perineal sonography are semi-critical medical products • These instruments should ideally be sterilised or at least disinfected in betw
Slide 14: Target Market Size
Target Market Size For personal use only Annual procedures Country / Region Radiology O&G Other Total Total intracavity intracavity targeted targeted available market market ANZ 0.5M 1M 0.2M 1.7M 5.8M Western Europe 7M 16M 3M 26M 70M Canada 0.4M 0.9M 0.2M 1.5M 3.6M US 7M 11M 9M 27M 87M Asia 8.2M 17M
Slide 15: Regulatory Requirements
Regulatory Requirements For personal use only 2009 Japan MOH Submission
Slide 16: Launch Timeline
Launch Timeline For personal use only 2010 Japan
Slide 17: Appointment of Distribution Channels
Appointment of Distribution Channels For personal use only Country / Region Dealer Status Australia Confirmed New Zealand Confirmed France Confirmed Germany Confirmed Italy Confirmed Scandinavia Confirmed Switzerland Confirmed
Slide 18: Distribution Model
Distribution Model For personal use only North America Envisaged •Sales office •Appointment of dealer network •Contracted Consumables Manufacture Europe Established •European Sales office Japan •Business Development Manager Envisaged •Statutory entity (legal protection) •Joint Venture •Appointment o
Slide 19: Manufacturing
For personal use only Manufacturing
Slide 20: Manufacturing Progress
Manufacturing Progress For personal use only • Tooling commenced Q4 FY08 • Procurement commenced Q1 FY09 • Commercial production on track for Jan 09 • Scalable capacity to meet targeted demand • In house assembly device • Outsourced consumable filling • Potential sub-contract manufacturer, critical
Slide 21: Product Pipeline
For personal use only Product Pipeline
Slide 22: Future Market Opportunities
Future Market Opportunities For personal use only NanoNebulant™ Platform Technology Currently in various stages of research and development TEE Decontamination in Food processing Medical / Healthcare •Agriculture customised products Endoscopes •Public Food applications Room / Industrial spaces Packa
Slide 23: Collaborative Developments
Collaborative Developments For personal use only
Slide 24: Show Me The Money!
“Show Me The Money!” For personal use only 9 CE Mark obtained May 08 9 EN ISO 13485:2003 quality approval 9 IP – portfolio of 10 patent families 9 Appointment of dealers on plan 9 Manufacturing on plan for Jan 09 9 Release in Australia on plan pending TGA approval 9 Strong product pipeline developin
Slide 25: For personal use only
eeeeoeeoeoeee ee ee ee ee @e @e
Nanosonics — Wilsons HTM Life Sciences Investment Conference (October 2008) on 6ix